Sign in
Taking people in United StatesNo phase

Visual Performance of Clareon PanOptix vs. a Comparable Multifocal Intraocular Lens

Key facts

Who runs it
Argus Research Center, Inc.
Where
Cape Coral, Gainesville, and Torrance, United StatesSee the 3 sites
Trial code
Status
Recruiting
People taking part
290 people, planned
Started
7 May 2025
Planned end
Nov 2025
Type of study
Interventional, 2 groups
Treatments tested
  • Clareon PanOptix or PanOptix Toric IOLs
  • Comparable multifocal IOL
Record updated
5 June 2025

Who can take part

Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 27 criteriaShow less

Who can take part

  • Stage 1: IIT Pilot
  • Willing and able to understand and sign informed consent
  • Adult patients previously diagnosed with age-related cataracts bilaterally
  • Previous bilateral age-related cataract removal and with bilateral implantation of the Clareon PanOptix/ Clareon PanOptix Toric (T3-T4) or Comparable Multifocal Intraocular Lens (equivalent to T3-T4) closest to 2.5-5-months after implantation and >2 weeks post YAG (if done) that were targeted for emmetropia
  • Best monocular corrected distance visual acuity was expected to be 0.1 logMAR (Snellen 20/25) or better in both eyes pre-operatively as determined by surgeon
  • Normal ocular findings aside from cataract; Stage 2: Comparison
  • Willing and able to understand and sign informed consent
  • Adult patient diagnosed with age-related cataracts bilaterally
  • Planned bilateral cataract removal by femtosecond laser-assisted phacoemulsification with bilateral implantation of the Clareon PanOptix/Clareon PanOptix Toric (T3-T4) or Comparable Multifocal Intraocular Lens (equivalent to T3-T4)
  • Best monocular corrected distance visual acuity expected to be 0.1 logMAR (Snellen 20/25) or better in both eyes postoperatively as determined by surgeon
  • Residual astigmatism expected to be ≤ 0.50 diopters in both eyes postoperatively as determined by surgeon (after using either toric IOL or arcuate incision with laser)
  • Normal ocular findings aside from cataract

Who cannot take part

  • Previous history of any ocular surgery including corneal refractive surgery
  • Previous history of any ocular surgery including corneal refractive surgery
  • Any planned simultaneous/combined procedures at time of cataract surgery (e.g. MIGs)
  • Corneal pathology, irregular astigmatism, preexisting macular disease and other retinal degenerative diseases, diabetic retinopathy that is expected to cause future vision loss, glaucoma, severe dry eye disease, nystagmus, strabismus, zonular laxity or dehiscence, pseudoexfoliation
  • Any active ocular infection or inflammation; Stage 2: Comparison
  • Corneal pathology, irregular astigmatism, preexisting macular disease and other retinal degenerative
  • diseases that is expected to cause future vision loss, glaucoma, severe dry eye disease, nystagmus, strabismus, zonular laxity or dehiscence, pseudoexfoliation
  • History of amblyopia or monofixation syndrome with poor stereoscopic vision
  • Any active ocular infection or inflammation
  • Stage 1: IIT Pilot
  • Participation in another clinical study that could interfere with the results
  • Patients with monovision correction
  • Participants desiring monovision
  • Total corneal HOA greater than 0.6um, coma less than 0.3um at 4mm-5mm scan depending on pre- op photopic topography
  • Participation in another clinical study that could interfere with the results

This trial is currently available in United States.

  • Tyson EyeCape Coral, United StatesContact: Angela HartlineTaking people
  • North Georgia Eye AssociatesGainesville, United StatesContact: MaryAnn ThomasTaking people
  • Wolstan & Goldberg Eye AssociatesTorrance, United StatesContact: Cynthia MontesTaking people

About the trial

What the trial wants to find out

This is a two-part, multi-center, investigator-initiated clinical study comparing visual outcomes and patient satisfaction in subjects receiving bilateral implantation of either the Clareon PanOptix intraocular lens (IOL) or a comparable multifocal IOL. The study includes a retrospective/prospective pilot phase and a prospective, randomized comparison phase.

The 2 groups in the trial

  • Clareon PanOptix or PanOptix Toric IOLsTreatment being tested
  • Comparable multifocal IOLTreatment being tested

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Visual Performance Differences Between Clareon PanOptix and a Comparable Multifocal Intraocular Lens
Record updated
5 June 2025